

Andrew M Tonkin

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/139217/publications.pdf>

Version: 2024-02-01

118
papers

7,592
citations

109321

35
h-index

54911

84
g-index

146
all docs

146
docs citations

146
times ranked

10771
citing authors

#	ARTICLE	IF	CITATIONS
1	Alcohol consumption and risks of cardiovascular disease and all-cause mortality in healthy older adults. <i>European Journal of Preventive Cardiology</i> , 2022, 29, e230-e232.	1.8	4
2	Comparison of statins for primary prevention of cardiovascular disease and persistent physical disability in older adults. <i>European Journal of Clinical Pharmacology</i> , 2022, 78, 467-476.	1.9	5
3	Cardiovascular risk prediction in healthy older people. <i>GeroScience</i> , 2022, 44, 403-413.	4.6	11
4	Associations between blood sex steroid concentrations and risk of major adverse cardiovascular events in healthy older women in Australia: a prospective cohort substudy of the ASPREE trial. <i>The Lancet Healthy Longevity</i> , 2022, 3, e109-e118.	4.6	15
5	A multistate model of health transitions in older people: a secondary analysis of ASPREE clinical trial data. <i>The Lancet Healthy Longevity</i> , 2022, 3, e89-e97.	4.6	10
6	Prognostic Value of a Polygenic Risk Score for Coronary Heart Disease in Individuals Aged 70 Years and Older. <i>Circulation Genomic and Precision Medicine</i> , 2022, 15, CIRCGEN121003429.	3.6	13
7	Safety of Ceasing Aspirin Used Without a Clinical Indication After Age 70 Years: A Subgroup Analysis of the ASPREE Randomized Trial. <i>Annals of Internal Medicine</i> , 2022, 175, 761-764.	3.9	8
8	Circulating Cystatin C Is an Independent Risk Marker for Cardiovascular Outcomes, Development of Renal Impairment, and Long-Term Mortality in Patients With Stable Coronary Heart Disease: The LIPID Study. <i>Journal of the American Heart Association</i> , 2022, 11, e020745.	3.7	14
9	Generation of cardio-protective antibodies after pneumococcal polysaccharide vaccine: Early results from a randomised controlled trial. <i>Atherosclerosis</i> , 2022, 346, 68-74.	0.8	7
10	Long-Term Treatment with the Combination of Rivaroxaban and Aspirin in Patients with Chronic Coronary or Peripheral Artery Disease: Outcomes During the Open Label Extension of the COMPASS trial. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 8, 786-795.	3.0	6
11	Trajectories of depressive symptoms in older adults and associated health outcomes. <i>Nature Aging</i> , 2022, 2, 295-302.	11.6	7
12	Does Aspirin Prevent Incident Heart Failure in Healthy Older Adults? Examining the Evidence From the ASPREE Trial. <i>Circulation: Heart Failure</i> , 2022, 15, .	3.9	1
13	B-type Natriuretic Peptide and Long-Term Cardiovascular Mortality in Patients With Coronary Heart Disease. <i>Journal of the American Heart Association</i> , 2022, 11, .	3.7	4
14	Cost-effectiveness of dapagliflozin in chronic heart failure: an analysis from the Australian healthcare perspective. <i>European Journal of Preventive Cardiology</i> , 2021, 28, 975-982.	1.8	35
15	Role of Cardiac Biomarkers in Epidemiology and Risk Outcomes. <i>Clinical Chemistry</i> , 2021, 67, 96-106.	3.2	9
16	Subgroup analysis of the ASPirin in Reducing Events in the Elderly randomized clinical trial suggests aspirin did not improve outcomes in older adults with chronic kidney disease. <i>Kidney International</i> , 2021, 99, 466-474.	5.2	18
17	Assessing and modifying cardiovascular risk in people who present to a chest pain clinic with non-cardiac causes. <i>Medical Journal of Australia</i> , 2021, 214, 263-264.	1.7	0
18	HIGH-SENSITIVITY CARDIAC TROPONIN T FOR THE DETECTION OF MYOCARDIAL INJURY AND RISK STRATIFICATION IN COVID-19. <i>Journal of the American College of Cardiology</i> , 2021, 77, 3145.	2.8	4

#	ARTICLE	IF	CITATIONS
19	PREDICTIVE PERFORMANCE OF A POLYGENIC RISK SCORE FOR INCIDENT ISCHEMIC STROKE IN A HEALTHY OLDER POPULATION. <i>Journal of the American College of Cardiology</i> , 2021, 77, 1471.	2.8	1
20	Genetic variants associated with inherited cardiovascular disorders among 13,131 asymptomatic older adults of European descent. <i>Npj Genomic Medicine</i> , 2021, 6, 51.	3.8	11
21	Protective lipid-lowering variants in healthy older individuals without coronary heart disease. <i>Open Heart</i> , 2021, 8, e001710.	2.3	1
22	Long-Term Blood Pressure Variability and Risk of Cognitive Decline and Dementia Among Older Adults. <i>Journal of the American Heart Association</i> , 2021, 10, e019613.	3.7	23
23	Risk stratification of cardiovascular complications using CHA2DS2-VASc and CHADS2 scores in chronic atherosclerotic cardiovascular disease. <i>International Journal of Cardiology</i> , 2021, 337, 9-15.	1.7	4
24	Predictive Performance of a Polygenic Risk Score for Incident Ischemic Stroke in a Healthy Older Population. <i>Stroke</i> , 2021, 52, 2882-2891.	2.0	15
25	Health-related quality of life and incident cardiovascular disease events in community-dwelling older people: A prospective cohort study. <i>International Journal of Cardiology</i> , 2021, 339, 170-178.	1.7	17
26	Effect of Atorvastatin on Knee Cartilage Volume in Patients With Symptomatic Knee Osteoarthritis: Results From a Randomized Placebo-Controlled Trial. <i>Arthritis and Rheumatology</i> , 2021, 73, 2035-2043.	5.6	7
27	Social isolation, social support and loneliness as predictors of cardiovascular disease incidence and mortality. <i>BMC Geriatrics</i> , 2021, 21, 711.	2.7	43
28	Development and validation of a ceramide- and phospholipid-based cardiovascular risk estimation score for coronary artery disease patients. <i>European Heart Journal</i> , 2020, 41, 371-380.	2.2	180
29	Vascular Pathology and Osteoarthritis: A Systematic Review. <i>Journal of Rheumatology</i> , 2020, 47, 748-760.	2.0	24
30	Factors Associated With Treatment and Control of Hypertension in a Healthy Elderly Population Free of Cardiovascular Disease: A Cross-sectional Study. <i>American Journal of Hypertension</i> , 2020, 33, 350-361.	2.0	5
31	Rivaroxaban for Prevention of Covert Brain Infarcts and Cognitive Decline. <i>Stroke</i> , 2020, 51, 2901-2909.	2.0	15
32	Impact of the 2017 American Heart Association and American College of Cardiology hypertension guideline in aged individuals. <i>Journal of Hypertension</i> , 2020, 38, 2527-2536.	0.5	3
33	Long-Term Blood Pressure Variability and Risk of Cardiovascular Disease Events Among Community-Dwelling Elderly. <i>Hypertension</i> , 2020, 76, 1945-1952.	2.7	21
34	Patterns of Association between Depressive Symptoms and Chronic Medical Morbidities in Older Adults. <i>Journal of the American Geriatrics Society</i> , 2020, 68, 1834-1841.	2.6	41
35	Familial Hypercholesterolemia in a Healthy Elderly Population. <i>Circulation Genomic and Precision Medicine</i> , 2020, 13, e002938.	3.6	8
36	Association of Statin Use With Disability-Free Survival and Cardiovascular Disease Among Healthy Older Adults. <i>Journal of the American College of Cardiology</i> , 2020, 76, 17-27.	2.8	27

#	ARTICLE	IF	CITATIONS
37	Genetic Variation in PEAR1, Cardiovascular Outcomes and Effects of Aspirin in a Healthy Elderly Population. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 108, 1289-1298.	4.7	13
38	Medically actionable pathogenic variants in a population of 13,131 healthy elderly individuals. <i>Genetics in Medicine</i> , 2020, 22, 1883-1886.	2.4	20
39	Hypertension prevalence in patients attending tertiary pain management services, a registry-based Australian cohort study. <i>PLoS ONE</i> , 2020, 15, e0228173.	2.5	10
40	The association of antihypertensive use and depressive symptoms in a large older population with hypertension living in Australia and the United States: a cross-sectional study. <i>Journal of Human Hypertension</i> , 2020, 34, 787-794.	2.2	25
41	Title is missing!. , 2020, 15, e0228173.		0
42	Title is missing!. , 2020, 15, e0228173.		0
43	Title is missing!. , 2020, 15, e0228173.		0
44	Title is missing!. , 2020, 15, e0228173.		0
45	Rationale, design, and baseline participant characteristics in the MRI and cognitive substudy of the cardiovascular outcomes for people using anticoagulation strategies trial. <i>International Journal of Stroke</i> , 2019, 14, 270-281.	5.9	11
46	Temporal Changes in Characteristics, Treatment and Outcomes of Heart Failure Patients Undergoing Percutaneous Coronary Intervention Findings From Melbourne Interventional Group Registry. <i>Heart Lung and Circulation</i> , 2019, 28, 1018-1026.	0.4	0
47	Reaching cardiovascular prevention guideline targets with a polypill-based approach: a meta-analysis of randomised clinical trials. <i>Heart</i> , 2019, 105, 42-48.	2.9	45
48	The cost-effectiveness of canakinumab for secondary prevention of cardiovascular disease: The Australian healthcare perspective. <i>International Journal of Cardiology</i> , 2019, 285, 1-5.	1.7	13
49	Stroke Outcomes in the COMPASS Trial. <i>Circulation</i> , 2019, 139, 1134-1145.	1.6	118
50	Association Between Statin Use and Depressive Symptoms in a Large Community-Dwelling Older Population Living in Australia and the USA: A Cross-Sectional Study. <i>CNS Drugs</i> , 2019, 33, 685-694.	5.9	8
51	Response by Simes et al to Letter Regarding Article, "D-Dimer Predicts Long-Term Cause-Specific Mortality, Cardiovascular Events, and Cancer in Patients With Stable Coronary Heart Disease". <i>Circulation</i> , 2019, 139, 1245-1246.	1.6	0
52	Evaluating recruitment strategies for <scp>AUSPICE</scp> , a large Australian community-based randomised controlled trial. <i>Medical Journal of Australia</i> , 2019, 210, 409-415.	1.7	12
53	Cost-effectiveness of low-dose rivaroxaban and aspirin versus aspirin alone in people with peripheral or carotid artery disease: An Australian healthcare perspective. <i>European Journal of Preventive Cardiology</i> , 2019, 26, 858-868.	1.8	19
54	Does Statin Benefits Patients with Heart Failure Undergoing Percutaneous Coronary Intervention? Findings from the Melbourne Interventional Group Registry. <i>Cardiovascular Drugs and Therapy</i> , 2018, 32, 57-64.	2.6	4

#	ARTICLE	IF	CITATIONS
55	A Systematic Review and Meta-analysis of the Factors Associated With Nonadherence and Discontinuation of Statins Among People Aged ≥65 Years. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2018, 73, 798-805.	3.6	46
56	D-Dimer Predicts Long-Term Cause-Specific Mortality, Cardiovascular Events, and Cancer in Patients With Stable Coronary Heart Disease. <i>Circulation</i> , 2018, 138, 712-723.	1.6	93
57	Mind the Gap: Mismatches Between Clinicians and Patients in Heart Failure Medication Management. <i>Cardiovascular Drugs and Therapy</i> , 2018, 32, 37-46.	2.6	4
58	Adherence and Persistence Among Statin Users Aged 65 Years and Over: A Systematic Review and Meta-analysis. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2018, 73, 813-819.	3.6	63
59	Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials. <i>Lancet, The</i> , 2018, 392, 1311-1320.	13.7	355
60	Effect of Aspirin on Disability-free Survival in the Healthy Elderly. <i>New England Journal of Medicine</i> , 2018, 379, 1499-1508.	27.0	392
61	Effect of Aspirin on All-Cause Mortality in the Healthy Elderly. <i>New England Journal of Medicine</i> , 2018, 379, 1519-1528.	27.0	591
62	Effect of Aspirin on Cardiovascular Events and Bleeding in the Healthy Elderly. <i>New England Journal of Medicine</i> , 2018, 379, 1509-1518.	27.0	770
63	The cost-effectiveness of PCSK9 inhibitors - The Australian healthcare perspective. <i>International Journal of Cardiology</i> , 2018, 267, 183-187.	1.7	23
64	Cost-effectiveness of rivaroxaban and aspirin compared to aspirin alone in patients with stable cardiovascular disease: An Australian perspective. <i>International Journal of Cardiology</i> , 2018, 270, 54-59.	1.7	24
65	LDL Cholesterol Is the Only Clinically Relevant Biomarker for Atherosclerotic Cardiovascular Disease (ASCVD) Risk. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 104, 235-238.	4.7	10
66	Baseline Characteristics of Participants in the ASPREE (ASpirin in Reducing Events in the Elderly) Study. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2017, 72, 1586-1593.	3.6	143
67	Rationale, Design and Baseline Characteristics of Participants in the Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) Trial. <i>Canadian Journal of Cardiology</i> , 2017, 33, 1027-1035.	1.7	133
68	Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. <i>New England Journal of Medicine</i> , 2017, 377, 1319-1330.	27.0	1,745
69	Predictors of incident heart failure in patients after an acute coronary syndrome: The LIPID heart failure risk-prediction model. <i>International Journal of Cardiology</i> , 2017, 248, 361-368.	1.7	17
70	Persistent psychological distress and mortality in patients with stable coronary artery disease. <i>Heart</i> , 2017, 103, 1860-1866.	2.9	50
71	Development of an Australian cardiovascular disease mortality risk score using multiple imputation and recalibration from national statistics. <i>BMC Cardiovascular Disorders</i> , 2017, 17, 17.	1.7	14
72	Healthcare expenditure on Indigenous and non-Indigenous Australians at high risk of cardiovascular disease. <i>International Journal for Equity in Health</i> , 2017, 16, 108.	3.5	7

#	ARTICLE	IF	CITATIONS
73	Carvedilol and Cardiac Biomarkers in Dialysis Patients: Secondary Analysis of a Randomized Controlled Trial. <i>Kidney and Blood Pressure Research</i> , 2017, 42, 1033-1044.	2.0	7
74	Patterns and Predictors of Adherence to Statin Therapy Among Older Patients: Protocol for a Systematic Review. <i>JMIR Research Protocols</i> , 2017, 6, e39.	1.0	4
75	Rationale and design of a randomized controlled trial of pneumococcal polysaccharide vaccine for prevention of cardiovascular events: The Australian Study for the Prevention through Immunization of Cardiovascular Events (AUSPICE). <i>American Heart Journal</i> , 2016, 177, 58-65.	2.7	33
76	Attitudes of Patients and Prescribing Clinicians to Polypharmacy and Medication Withdrawal in Heart Failure. <i>Journal of Cardiac Failure</i> , 2016, 22, 743-744.	1.7	7
77	The treatment gap in patients with chronic systolic heart failure: a systematic review of evidence-based prescribing in practice. <i>Heart Failure Reviews</i> , 2016, 21, 675-697.	3.9	39
78	Plasma Lipidomic Profiles Improve on Traditional Risk Factors for the Prediction of Cardiovascular Events in Type 2 Diabetes Mellitus. <i>Circulation</i> , 2016, 134, 1637-1650.	1.6	205
79	Polypharmacy in heart failure – Is reducing medication safe?. <i>International Journal of Cardiology</i> , 2016, 214, 529-530.	1.7	4
80	Do polypills lead to neglect of lifestyle risk factors? Findings from an individual participant data meta-analysis among 3140 patients at high risk of cardiovascular disease. <i>European Journal of Preventive Cardiology</i> , 2016, 23, 1393-1400.	1.8	14
81	HealthMap: a cluster randomised trial of interactive health plans and self-management support to prevent coronary heart disease in people with HIV. <i>BMC Infectious Diseases</i> , 2016, 16, 114.	2.9	12
82	The β -Blocker to Lower Cardiovascular Dialysis Events (BLOCADE) Feasibility Study: A Randomized Controlled Trial. <i>American Journal of Kidney Diseases</i> , 2016, 67, 902-911.	1.9	36
83	Does statin use have a disease modifying effect in symptomatic knee osteoarthritis? Study protocol for a randomised controlled trial. <i>Trials</i> , 2015, 16, 584.	1.6	21
84	The Effect of a Cardiovascular Polypill Strategy on Pill Burden. <i>Cardiovascular Therapeutics</i> , 2015, 33, 347-352.	2.5	25
85	Impact of Fine Particulate Matter (PM _{2.5}) Exposure During Wildfires on Cardiovascular Health Outcomes. <i>Journal of the American Heart Association</i> , 2015, 4, .	3.7	168
86	Prediction of Cardiovascular and All-Cause Mortality at 10 Years in the Hypertensive Aged Population. <i>American Journal of Hypertension</i> , 2015, 28, 649-656.	2.0	16
87	Digoxin Withdrawal Worsens Clinical Status in Stable Patients With Heart Failure Receiving Optimal Contemporaneous Therapy – A Randomized Controlled Trial. <i>Journal of Cardiac Failure</i> , 2015, 21, 779-781.	1.7	7
88	Comparison of anthropometric measures as predictors of cancer incidence: A pooled collaborative analysis of 11 Australian cohorts. <i>International Journal of Cancer</i> , 2015, 137, 1699-1708.	5.1	46
89	Biomarkers in stable coronary heart disease, their modulation and cardiovascular risk: The LIPID biomarker study. <i>International Journal of Cardiology</i> , 2015, 201, 499-507.	1.7	42
90	A pragmatic randomized trial of a polypill-based strategy to improve use of indicated preventive treatments in people at high cardiovascular disease risk. <i>European Journal of Preventive Cardiology</i> , 2015, 22, 920-930.	1.8	136

#	ARTICLE	IF	CITATIONS
91	An economic case for a cardiovascular poly-pill? A cost analysis of the Kanyini GAP trial. <i>Medical Journal of Australia</i> , 2014, 201, 671-673.	1.7	18
92	Statins in the elderly. <i>Current Opinion in Cardiology</i> , 2014, 29, 372-380.	1.8	14
93	Can Medications be Safely Withdrawn in Patients With Stable Chronic Heart Failure? Systematic Review and Meta-analysis. <i>Journal of Cardiac Failure</i> , 2014, 20, 522-532.	1.7	36
94	Midregional proadrenomedullin and its change predicts recurrent major coronary events and heart failure in stable coronary heart disease patients: The LIPID study. <i>International Journal of Cardiology</i> , 2014, 172, 411-418.	1.7	15
95	Reversing social disadvantage in secondary prevention of coronary heart disease. <i>International Journal of Cardiology</i> , 2014, 171, 346-350.	1.7	9
96	Association of Contemporary Sensitive Troponin I Levels at Baseline and Change at 1 Year With Long-Term Coronary Events Following Myocardial Infarction or Unstable Angina. <i>Journal of the American College of Cardiology</i> , 2014, 63, 345-354.	2.8	61
97	Treatment of dyslipidemia. <i>F1000prime Reports</i> , 2014, 6, 17.	5.9	10
98	Plasma Lipoprotein(a) Concentration Predicts Future Coronary and Cardiovascular Events in Patients With Stable Coronary Heart Disease. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2013, 33, 2902-2908.	2.4	111
99	Changes in Lipoprotein-associated Phospholipase A2 Activity Predict Coronary Events and Partly Account for the Treatment Effect of Pravastatin: Results From the Long-term Intervention with Pravastatin in Ischemic Disease Study. <i>Journal of the American Heart Association</i> , 2013, 2, e000360.	3.7	47
100	A Pilot Study of Effects of Fruit Intake on Cardiovascular Risk Factors in Children. <i>ICAN: Infant, Child, & Adolescent Nutrition</i> , 2012, 4, 348-354.	0.2	1
101	Into the future: diversifying lipid management. <i>Lancet, The</i> , 2012, 380, 1971-1974.	13.7	6
102	Effects of fenofibrate on cardiovascular events in patients with diabetes, with and without prior cardiovascular disease: The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. <i>American Heart Journal</i> , 2012, 163, 508-514.	2.7	24
103	AUSDRISK: an Australian Type 2 Diabetes Risk Assessment Tool based on demographic, lifestyle and simple anthropometric measures. <i>Medical Journal of Australia</i> , 2010, 192, 197-202.	1.7	250
104	Effects of Combination Lipid Therapy in the Management of Patients With Type 2 Diabetes Mellitus in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial. <i>Circulation</i> , 2010, 122, 850-852.	1.6	37
105	Should aspirin be used for the primary prevention of cardiovascular disease in people with diabetes?. <i>Medical Journal of Australia</i> , 2009, 191, 356-357.	1.7	1
106	Where on the Healthcare Continuum Should We Invest? The Case for Primary Care?. <i>Heart Lung and Circulation</i> , 2009, 18, 108-113.	0.4	5
107	Cost-effectiveness of cholesterol-lowering therapy with pravastatin in patients with previous acute coronary syndromes aged 65 to 74 years compared with younger patients: Results from the LIPID study. <i>American Heart Journal</i> , 2006, 151, 1305-1312.	2.7	22
108	Unanswered Questions Arising from the Continuous Relationship Between Glucometabolic State and Cardiovascular Risk. <i>Current Atherosclerosis Reports</i> , 2006, 8, 439-440.	4.8	0

#	ARTICLE	IF	CITATIONS
109	White Blood Cell Count Predicts Reduction in Coronary Heart Disease Mortality With Pravastatin. <i>Circulation</i> , 2005, 111, 1756-1762.	1.6	59
110	The metabolic syndrome(s)?. <i>Current Atherosclerosis Reports</i> , 2004, 6, 165-166.	4.8	8
111	Risk prediction: Increasingly important, but questions still remain. <i>Current Atherosclerosis Reports</i> , 2003, 5, 1-2.	4.8	1
112	Accuracy of the Australian National Death Index: comparison with adjudicated fatal outcomes among Australian participants in the Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) study. <i>Australian and New Zealand Journal of Public Health</i> , 2003, 27, 649-653.	1.8	123
113	Coronary Heart Disease in Patients With Low LDL-Cholesterol. <i>Circulation</i> , 2002, 105, 1424-1428.	1.6	169
114	Long-term risk stratification for survivors of acute coronary syndromes. <i>Journal of the American College of Cardiology</i> , 2001, 38, 56-63.	2.8	112
115	The need for medicine-based evidence as well as evidence-based medicine. <i>Current Atherosclerosis Reports</i> , 2001, 3, 97-98.	4.8	0
116	Susceptibility to Atrial Fibrillation:.. <i>Journal of Cardiovascular Electrophysiology</i> , 1998, 9, 423-435.	1.7	54
117	VALIDATION OF AN ECHOCARDIOGRAPHIC ASSESSMENT OF CARDIAC FUNCTION FOLLOWING MODERATE SIZE MYOCARDIAL INFARCTION IN THE RAT. <i>Clinical and Experimental Pharmacology and Physiology</i> , 1996, 23, 570-572.	1.9	37
118	Adverse effects of low-dose aspirin in a healthy elderly population. <i>Clinical Pharmacology and Therapeutics</i> , 1993, 54, 84-89.	4.7	120